Amrutanjan Health Care FY26: Profit Jumps 14% on Strong Category Growth

Revenue grew to Rs 502.55 crore, while Profit After Tax reached Rs 57.92 crore.

Reader Takeaway: Robust hygiene and pain segment sales drive performance, though inflation and regulatory hurdles remain key monitoring points.

What just happened

Amrutanjan Health Care released its FY2026 Annual Report, showcasing a resilient financial performance despite global inflationary headwinds. The company reported a 14% increase in Profit After Tax (PAT) and an 11% rise in revenue from operations. The Board has recommended a final dividend of Rs 2.90 per share.

Why this matters

The results highlight the successful scaling of the company’s core categories. The pain management portfolio grew by 10%, while the 'Comfy' women's hygiene brand saw a strong 19% growth. These figures indicate that the company’s focus on deeper market penetration—adding 44,000 chemist outlets this year—is yielding tangible results.

What changes now

The company is gearing up for a major operational shift with a new greenfield sanitary napkin plant in Telangana. Commissioning in Q1 FY2027, this facility is expected to improve supply chain control and profitability for the Comfy brand. Additionally, the company is pushing toward 85% process digitization through new management systems.

Risks to watch

Management cited cost-of-goods-sold (COGS) inflation stemming from global supply chain disruptions and geopolitical tensions in the Middle East. Furthermore, the electrolyte drink category has faced significant regulatory challenges over the last three years, which continues to act as a constraint on growth for that specific segment.

What to track next

Investors should look for the timely commissioning of the Telangana plant and the company's progress toward its target of 100,000 direct chemist outlets by FY2027. These milestones will be central to maintaining the current margin trajectory.